David Curfman, MD
Vascular Neurology · Nashville, TNNPI 1619263720
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 39.6% of the total. Reporting peaked in 2019 at $1,140 and has fallen 57.7% since, to $482 in 2022.
Across 241 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$205
- Amneal Pharmaceuticals LLC$175
- Supernus Pharmaceuticals, Inc.$149
- Biohaven Pharmaceutical Holding Company Ltd.$136
- Biohaven Pharmaceuticals, Inc.$136
- plus $1K from 31 others
What the payments were for
- Speaking & faculty fees$461%
- Food & beverage$3,37299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,353 |
| Amgen | 12 | $205 |
| Amneal Pharmaceuticals LLC | 10 | $175 |
| Supernus Pharmaceuticals, Inc. | 7 | $149 |
| Biohaven Pharmaceutical Holding Company Ltd. | 21 | $136 |
| Biohaven Pharmaceuticals, Inc. | 27 | $136 |
| Teva Pharmaceuticals USA, Inc. | 5 | $108 |
| Greenwich Biosciences, Inc. | 5 | $97 |
| Upsher-smith Laboratories LLC | 5 | $93 |
| UCB, Inc. | 5 | $86 |
| Johnson & Johnson | 4 | $76 |
| Lilly USA, LLC | 5 | $68 |
| Avanir Pharmaceuticals, Inc. | 4 | $66 |
| Biogen | 4 | $60 |
| Lundbeck LLC | 3 | $54 |
| Acadia Pharmaceuticals Inc | 2 | $48 |
| Acorda Therapeutics, Inc | 2 | $46 |
| Sanofi | 2 | $44 |
| Grifols USA, LLC | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Avion Pharmaceuticals | 1 | $33 |
| Zyla Life Sciences, Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 2 | $31 |
| Genentech USA, Inc. | 2 | $29 |
| EMD Serono, Inc. | 2 | $28 |
| Eisai Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Bayer | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| SK Life Science, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Promius Pharma LLC | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
| Kyowa Kirin, Inc. | 1 | $12 |
How this compares
Too few vascular neurology providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 62 | $52,398 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $31,103 |
| UbrelvyUbrogepant | 20 | $19,855 |
| EliquisApixaban | 17 | $16,159 |
| Nurtec OdtRimegepant Sulfate | 16 | $15,898 |
| Topiramate ErTopiramate | 12 | $9,219 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 27 | $1,225 |
| Gabapentin | 55 | $1,171 |
| Atorvastatin Calcium | 67 | $929 |
| Levetiracetam | 33 | $911 |
| Topiramate | 26 | $524 |
| Duloxetine Hcl | 25 | $412 |
| Rosuvastatin Calcium | 16 | $338 |
| Nortriptyline Hcl | 16 | $320 |
| Donepezil Hcl | 13 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $1,353 | $19,85520 claims |
| Upsher-smith Laboratories LLCTopiramate | $93 | $52426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other vascular neurology in Nashville
- Deborah KerriganNashville$7K
- Himanshu PatelNashville$6K
- David ParrellaNashville$5K
- Phaniraj IyengarNashville$618
- Zunir ChaudhryNashville$164
- Matthew SchragNashville$116
- Carolyn CroninNashville$23
- Violiza AcostaMemphis$105K
- Charles CapeGermantown$2K
- Kaushik ParshaMemphis$786
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.